ArticleFrontiers in immunology2026
Development and computational analysis of high dimensional spectral flow cytometry data for the resolution of innate lymphoid cells in the mammary tumor microenvironment.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Special Issue "Flow Cytometry: Applications and Challenges".International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spectral flow cytometry has ushered in a new era in immunology. Through the improvement of the resolution of surface and intracellular protein expression, this approach enables in depth characterization of rare immune cell subsets, such as innate lymphoid cells (ILCs), in health and disease. Due to their heterogeneity, the identification of ILCs requires the use of many lineage marker antibodies for non-ILC exclusion, together with the analysis of several transcription factor expression profiles for ILC subset distinction. Such intricacies toward their identification and their scarcity in tissues have been key factors directly limiting their characterization, particularly during tumor development and progression. We developed, optimized and validated a 25-parameter spectral flow cytometric panel for the identification of mouse ILC subsets and characterization of their phenotype and proliferation capabilities in mouse mammary tumors. The use of conjugated antibodies coupled to different fluorochromes for the analysis of lineage marker expression further allows the identification and characterization of γδ T cells, CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.